My Unusual Body Recomp Stack

In January 2026, several oral GLP-1 drugs were competing for attention. Their results made me think about my own experience with weight-management medicines.

One question mattered beyond weight loss: which treatments could people tolerate well enough to keep taking?

I wanted to compare that question with a different medicine I was trying: acarbose. It can change glucose handling, but it is not equivalent to a GLP-1 drug.

The TL;DR if you only have 30 seconds:

• Oral GLP-1s: Why gastrointestinal side effects still matter.
• My experience: Food tracking, exercise, and an off-label acarbose experiment.
• Habits: What a study of sleep, movement, and nutrition found, and why its lifespan estimates are not a prescription.
• Quick Hits: Neural stem-cell research, a drug-development deal, and genetic evidence on vascular dementia.

Let's get into it.

Oral GLP-1s: efficacy and tolerability both matter

Weight-loss efficacy is not “solved.” The size and durability of the effect, side effects, dosing, and long-term safety all matter.

Corxel announced financing for its oral GLP-1 program in January 2026. Funding did not show that its candidate was better than a competitor.

A pill does not guarantee fewer side effects

Viking’s August 2025 phase 2 report found up to 12.2% average weight loss over thirteen weeks with oral VK2735. That was the result in a particular dose group; separate trials cannot establish that it was the fastest treatment in development.

Then you read the side effect table:

• Nausea: 58% across active-treatment groups, versus 48% with placebo.
• Vomiting: 26% across active-treatment groups, versus 10% with placebo.

Those side effects deserve attention. They don’t show that every oral GLP-1 is harder to tolerate than every injectable.

🔬 The Mechanism (For the Clinically Curious)

Why does this happen? It's not a manufacturing flaw. It's the biology.

GLP-1 signaling affects appetite, digestion, and nausea through several gut and brain pathways. Drug dose, escalation, formulation, and the person’s response all affect tolerability.

More exposure can bring more side effects, but the relationship differs between medicines and doses.

Slow dose escalation can help some people. It doesn’t guarantee that nausea will resolve, and side effects are not the only basis for choosing a treatment.

Acarbose works differently

There's another way to raise GLP-1 without touching the receptor directly.

You let the gut do it for you.

Acarbose inhibits enzymes that break down some carbohydrates in the small intestine. It delays glucose absorption after a meal, and more carbohydrate can reach the colon for fermentation.

Changes in fermentation and gut hormones are part of the research on acarbose. Mouse microbiome findings do not establish that butyrate explains its effects in a person.

That mechanism does not make acarbose a gentler equivalent of semaglutide or prove that it avoids all brain or nausea effects.

Gas, diarrhea, and abdominal discomfort are common with acarbose. Some people improve over time; others cannot tolerate it. A direct comparison trial would be needed to rank its tolerability against a GLP-1 drug.

Why acarbose interests aging researchers

Acarbose extended lifespan in genetically varied mice in the NIA Interventions Testing Program, with follow-up work at several doses. It is one of several effective agents in that mouse program, not an established human longevity drug.

In the earlier experiment, median lifespan increased about 22% in males and 5% in females. Sex, dose, and mouse biology matter; these percentages cannot predict a benefit for me or my patients.

The mechanism likely goes beyond GLP-1:

• Reduced postprandial glucose excursions

• Improved insulin sensitivity

• Possible effects on the microbiome-gut-brain axis

• Butyrate's role in gut barrier integrity and inflammation

Those findings explain why I follow the research. They don’t make acarbose an approved treatment for human aging or a substitute for a weight-loss medicine.

The tradeoff is worth understanding before trying it.

Clinical note: Acarbose is approved for glucose management in adults with type 2 diabetes. Its label lists bowel and liver contraindications, cautions about significant kidney dysfunction, and dose-related adverse effects. Off-label use needs a prescriber’s review; this article is not a starting-dose or titration plan.

What I take from the comparison

I care about the results and what it feels like to keep taking the medicine. Price and an appealing mechanism can’t answer both questions.

For me, acarbose was an experiment with glucose handling and appetite. Human healthspan benefits remain uncertain.

I've been testing it myself. Here's the protocol 👇

Subscribe or share our newsletter for longevity updates

⚡ The CEO Protocol: My Body Recomp Plan

After no fewer than six conferences in Q4 2025 (then straight into the holiday season), my January goal was probably the same as yours: body recomposition.

I've seen the miracles of GLP-1s firsthand. Patients losing 50, 80, 100+ pounds. Metabolic panels normalizing. Lives transformed. I'm a believer in the drug class.

But when I tried them myself (even at micro doses)? Different story.

When I tried low doses, I noticed ankle swelling, dry mouth, and anhedonia: that flat, unmotivated, “what’s the point” feeling. I suspected the medicine contributed, but my experience does not prove the mechanism or establish these as effects everyone should expect.

So I made a decision to do it the old school way...plus something different.

The Stack:

• MacroFactor: I tracked every meal, weighed food, and prepared meals in advance. The accountability was annoying and non-negotiable.

• Protein: My target was over one gram per pound of body weight, with protein at each meal. That was my target, not a requirement for every reader.

• Food intake: I aimed for about 115 grams of carbohydrate and a 250-calorie daily deficit. This helped me manage hunger; it does not mean carbohydrates as a group are addictive.

• Exercise: I combined cardio and resistance work, sometimes twenty minutes on the treadmill plus lifting, and used the sauna about three times a week.

• Acarbose: I used 50 mg with carbohydrate-containing meals. I felt fuller than expected. Feeling fuller does not establish a particular GLP-1 or butyrate effect.

• Exogenous ketones: I sometimes used them for focus or hunger. Honestly, I’m still not sure they helped; they also contain energy and count toward intake.

• CGM: I saw fewer large glucose excursions over the month. Diet, activity, medicine, and measurement variation could all contribute.

My tracking screenshots

The Result So Far:

I was down about five pounds that month, and progress photos looked different. I suspected I had lost fat and gained muscle, but weight, photos, and a home scale cannot confirm those changes separately.

The pace was slower than I had hoped for.

Is it more psychological effort? Absolutely.

I’ll take the bloat over how I felt on GLP-1s. That is my tradeoff; someone else may make a different choice.

Note: Acarbose is a prescription drug. ZBiotics’ Sugar-to-Fiber product is a different commercial product, not an equivalent over-the-counter treatment. This comparison does not establish liver protection or a human longevity benefit for that probiotic.

Small changes in sleep, movement, and food

A 2026 eClinicalMedicine cohort study looked at how sleep, activity, and diet related to later health. It found associations; it did not assign people a small daily change and then measure extra years of life.

Related research: sleep, activity, and diet study.

The analysis included 59,078 UK Biobank adults and about eight years of follow-up. Sleep and movement came from a week of accelerometer data; diet came from a reported diet-quality score.

What the model found

The model associated a modest combined improvement, starting from very unfavorable habits, with about one additional year of estimated life expectancy.

The modeled combination was:

• About five more minutes of sleep.
• About two more minutes of moderate-to-vigorous activity.
• A small improvement in the diet-quality score.

These are statistical estimates, not minimum daily prescriptions.

Sleep, movement, and food are worth working on together. The study cannot tell one person how many minutes will add a year to their life.

What's MVPA?

MVPA = Moderate-to-Vigorous Physical Activity

Basically, anything that gets your heart rate up beyond a casual stroll. Think:

• Brisk walking

• Cycling

• Swimming

• Strength training

• Running

• Tennis, pickleball, etc.

The study defined it using accelerometer data: activities hitting ≥3 METs (metabolic equivalent tasks).

The Maximum Upside

The most favorable habit groups had substantially longer modeled life and health expectancy than the least favorable groups. Confounding, prior illness, and changes in habits can affect that comparison.

My practical takeaway is to improve the habit that is easiest to change, then build on it. You do not need to perfect one area before working on another.

⚡ Longevity Quick Hits

🧠 Neural stem-cell research: NUS researchers studied DMTF1 in aging-related cell models. The findings suggest a mechanism to study, not a proven way to rejuvenate a human brain or treat cognitive decline.

🧬 An AI drug-development deal: In January 2026, Insilico Medicine and Qilu announced a collaboration to design small molecules for cardiometabolic disease. Business interest doesn’t tell us whether a treatment will work in patients.

📉 BMI and vascular dementia: A genetic analysis supports a possible causal role for higher BMI in vascular-related dementia. Mendelian randomization depends on assumptions about the genetic instruments; it does not prove that any particular weight-loss or blood-pressure treatment prevents dementia.

Related research: BMI and vascular-dementia analysis.

🫀 Until Next Week

If this issue made you think differently about the GLP-1 hype, or gave you permission to try the boring fundamentals first, forward it to someone who needs to hear it.

And if you're a clinician interested in the off-label longevity stack (Acarbose, metformin, rapamycin, the usual suspects), I'm always happy to trade notes. Just reply.

To your healthspan,

Hillary Lin, MD

Co-Founder & CEO

​Curator​

Follow me for more longevity insights:YouTube|LinkedIn|Instagram|TikTok​

Learn about Curator’s platform.

Events listed when this issue was published

Physician Creator Trends – VSP Innovation Center & Matter Fireside Chat (Virtual) – Jan 28 @ 1PM ESTlink here. So excited about this topic!

👱🏻‍♀️👩🏻‍🦰👩🏻👧🏽👧🏾 Livelong Women’s Health Summit – April 17-18, 2026, SF, CA. Delighted to join 50 other thought leaders in speaking on women's longevity!​

Offers listed when this issue was published

This issue included an affiliate offer from NeuroAgeTx. I may earn a commission from qualifying purchases. Check current services and prices before buying.

This issue included a Timeline offer. A four-week urolithin A trial found changes in selected immune-cell measures, not proof of longer life or fewer infections. Check current offer terms.

GlycanAge reports an age estimate from IgG glycosylation. It doesn’t diagnose the cause of inflammation or establish a treatment.

I have liked ZBiotics products. That preference is not proof that they extend life or offset alcohol’s health risks. Check current offer terms.